Atlas Trials

Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.

Clinical trial NCT07615413 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07615413
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
KRAS G12C Mutation Advanced Solid Tumor
Start date
2026-06-30
Primary completion
2029-06-30
Enrollment
636

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.